Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8048)
◆英語タイトル:Ohr Pharmaceutical Inc (OHRP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8048
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthalmic solution is used in wet age-related macular degeneration, retinal vein occlusion, proliferative diabetic retinopathy and diabetic macular edema indications. Ohr has a sustained-release micro-fabricated micro-particle ocular drug delivery platform technology that utilizes hydrogel template approach to prepare microparticles or other configurations. The company also conducts programs for the treatment of ocular conditions including primary open angle glaucoma, steroid-induced glaucoma, ocular allergy, and retinal diseases. It operates through its research facilities in San Diego, the US. Ohr is headquartered in New York, the US.

Ohr Pharmaceutical Inc (OHRP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ohr Pharma Completes Acquisition of Ophthalmology Assets from SKS Ocular 10
Partnerships 11
Ohr Pharma Forms Joint Venture With Cold Spring Harbor Lab 11
Licensing Agreements 12
Vitrisa Therapeutics Enters into Option Agreement with Ohr Pharma 12
Equity Offering 13
Ohr Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 13
Ohr Pharma Raise USD14.2 Million in Public Offering of Shares and Warrants 14
Ohr Pharmaceutical Raises USD7.8 Million in Public Offering of Shares and Warrants 16
Ohr Pharma Raises USD29 Million Public Offering of Shares 17
Ohr Pharma Completes Private Placement Of Shares For US$18 Million 19
Ohr Pharma Raises USD0.4 Million in Private Placement of Shares 20
Ohr Pharma Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 21
Ohr Pharma Completes Private Placement Of Shares For US$2.9 Million Upon Exercise Of Warrants 22
Ohr Pharmaceutical Inc – Key Competitors 23
Ohr Pharmaceutical Inc – Key Employees 24
Ohr Pharmaceutical Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Aug 14, 2018: Ohr Pharmaceutical reports fiscal third quarter 2018 financial results 26
May 15, 2018: Ohr Pharmaceutical Announces Fiscal Second Quarter 2018 Financial Results 27
Feb 14, 2018: Ohr Pharmaceutical Reports Q1 Fiscal 2018 Financial Results 28
Dec 15, 2017: Ohr Pharmaceutical Reports Fiscal Year 2017 Financial Results 29
Aug 08, 2017: Ohr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings 30
May 11, 2017: Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings 32
Feb 14, 2017: Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings 33
Corporate Communications 34
May 11, 2017: Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors 34
Product News 35
01/05/2018: Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD 35
Clinical Trials 36
Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ohr Pharma Completes Acquisition of Ophthalmology Assets from SKS Ocular 10
Ohr Pharma Forms Joint Venture With Cold Spring Harbor Lab 11
Vitrisa Therapeutics Enters into Option Agreement with Ohr Pharma 12
Ohr Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 13
Ohr Pharma Raise USD14.2 Million in Public Offering of Shares and Warrants 14
Ohr Pharmaceutical Raises USD7.8 Million in Public Offering of Shares and Warrants 16
Ohr Pharma Raises USD29 Million Public Offering of Shares 17
Ohr Pharma Completes Private Placement Of Shares For US$18 Million 19
Ohr Pharma Raises USD0.4 Million in Private Placement of Shares 20
Ohr Pharma Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 21
Ohr Pharma Completes Private Placement Of Shares For US$2.9 Million Upon Exercise Of Warrants 22
Ohr Pharmaceutical Inc, Key Competitors 23
Ohr Pharmaceutical Inc, Key Employees 24
Ohr Pharmaceutical Inc, Joint Venture 25

List of Figures
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報(Ohr Pharmaceutical Inc (OHRP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆